Having demonstrated the high preferential activity of TOPK inhibitor OTS514 in AML cell lines and primary blasts with FLT3-ITD mutation, we attempted to examine the in vivo activity of this compound using a previously established FLT3-ITD engraft murine model [42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.